Baxter International

BAX · NYSE · Health Care Equipment

Health Care Equipment company based in Deerfield, Illinois.

In the last 90 days, no insider of Baxter International reported an open-market purchase and 0 open-market sales. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.

Last close, Oct 5, 2026

$24.22

Adjusted for splits and dividends

Last 12 months

+1.5%

S&P 500 +15.8% over the same dates

Market value

$12.5B

Last close × shares outstanding

BAX price and disclosed trades

Last 12 months, adjusted daily closes

Congress purchase 1
Congress sale 2

Each mark is a disclosed trade, placed on its trade date. Past moves are not a forecast. Trades by one person on the same day share a mark. Congress amounts are official ranges; mark size uses the lower bound.

Show these trades as a list

Rep. Lisa McClain (MI09) · Congress sale, reported range $1,001 - $15,000Oct 31, 2025
Rep. Lisa McClain (MI09) · Congress purchase, reported range $1,001 - $15,000Oct 30, 2025
Rep. Lisa McClain (MI09) · Congress sale, reported range $1,001 - $15,000Oct 30, 2025

Bets against the stock: 23.2M shares sold short (4.5% of shares outstanding), -0.3% vs the previous count, 4.5 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.

Latest results: quarter ending Jun 30, 2026

Revenue

$2.96B

+5.3% vs the same quarter a year earlier

Free cash flow, last 12 months

—

Cash from operations minus capital spending

Net debt

—

Debt —, cash $2.15B, at Jun 30, 2026

Backlog

$7.91B

Work contracted but not yet delivered, as the company reports it

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 30, 2026.

Insiders buying, last 90 days

None

No open-market purchases reported

Insiders selling, last 90 days

None

No open-market sales reported

New federal contracts, 12 months

None

Nothing found for this company

Company size

10-K filed Feb 12, 2026

Revenue, fiscal 2025

$11.2B

+5.7% vs the year before

Net income, fiscal 2025

-$957M

A loss for the year

Shares outstanding

517M

As of Jul 23, 2026

In fiscal 2025 the company spent $348M on dividends. Cash actually paid, from its cash-flow statement.

Red flags in its filings

Aug 19
Top officer leaving
“Appointment of Andrew Hider as Interim CFO As previously announced, Anita Zielinski, the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, will depart the Company, effective as of September 15, 2026.”
8-K on sec.gov
Aug 4
Top officer leaving
“(the “Company”) of her decision to resign as the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective as of September 15, 2026, to join another company.”
8-K on sec.gov
Nov 12
Top officer leaving
“(the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry.”
8-K on sec.gov
Oct 21
Top officer leaving
“(the “Company”) of her decision to resign as the Company’s Executive Vice President, Chief Operating Officer (“COO”) and interim group president of Medical Products and Therapies (“MPT”), effective as of October 29, 2025 (the “Transition Date”), to join a company in the healthcare industry.”
8-K on sec.gov

From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.

Holders above 5%

Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.

Legal

A securities lawsuit naming the company as a defendant was filed on Dec 3, 2025 in the U.S. District Court, N.D. Illinois. A filing is an allegation, not a finding.
City of Hallandale Beach Police Officers' and Firefighters' Personnel Retirement Trust v. Baxter International, Inc., 1:25-cv-14712
A securities lawsuit naming the company as a defendant was filed on Oct 16, 2025 in the U.S. District Court, N.D. Illinois. A filing is an allegation, not a finding.
Electrical Workers Pension Fund, Local 103 IBEW v. Baxter International, Inc., 1:25-cv-12672

Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.

FDA, last 12 months

14 approvals or clearances and 39 recalls recorded by the FDA for this company and its listed subsidiaries.

Approvals and clearances

Recalls

From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.

Named in the Federal Register

Nov 24
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Final rule · Centers for Medicare & Medicaid Services

Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.

Latest

See everything

8w ago

Fund moves

17KShares reported · +1,282 vs prior quarter

From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.

Why it stands out Official record

8mo ago

5%+ stake

6.8%

Stake

A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.

Why it stands out Official record

11mo ago

Congressional trade

$1,001 - $15,000Reported range · official band, not an exact amount

Held by the filer's spouse per the disclosure. Disclosed 22 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

11mo ago

Congressional trade

$1,001 - $15,000Reported range · official band, not an exact amount

Held by the filer's spouse per the disclosure. Disclosed 22 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

11mo ago

Congressional trade

$1,001 - $15,000Reported range · official band, not an exact amount

Held by the filer's spouse per the disclosure. Disclosed 21 days after the transaction; reported as an official range, not an exact amount.

Why it stands out Official record

Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.

Legal

A securities lawsuit naming the company as a defendant was filed on Dec 3, 2025 in the U.S. District Court, N.D. Illinois. A filing is an allegation, not a finding.
City of Hallandale Beach Police Officers' and Firefighters' Personnel Retirement Trust v. Baxter International, Inc., 1:25-cv-14712
A securities lawsuit naming the company as a defendant was filed on Oct 16, 2025 in the U.S. District Court, N.D. Illinois. A filing is an allegation, not a finding.
Electrical Workers Pension Fund, Local 103 IBEW v. Baxter International, Inc., 1:25-cv-12672

Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.

Holders above 5%

Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.

BAX price and disclosed trades

Last 12 months, adjusted daily closes

Congress purchase 1
Congress sale 2

Each mark is a disclosed trade, placed on its trade date. Past moves are not a forecast. Trades by one person on the same day share a mark. Congress amounts are official ranges; mark size uses the lower bound.

Show these trades as a list

Rep. Lisa McClain (MI09) · Congress sale, reported range $1,001 - $15,000Oct 31, 2025
Rep. Lisa McClain (MI09) · Congress purchase, reported range $1,001 - $15,000Oct 30, 2025
Rep. Lisa McClain (MI09) · Congress sale, reported range $1,001 - $15,000Oct 30, 2025

Named in the Federal Register

Nov 24
Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model
Final rule · Centers for Medicare & Medicaid Services

Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.

Red flags in its filings

Aug 19
Top officer leaving
“Appointment of Andrew Hider as Interim CFO As previously announced, Anita Zielinski, the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, will depart the Company, effective as of September 15, 2026.”
8-K on sec.gov
Aug 4
Top officer leaving
“(the “Company”) of her decision to resign as the Company’s Interim Chief Financial Officer and Senior Vice President, Chief Accounting Officer and Controller, effective as of September 15, 2026, to join another company.”
8-K on sec.gov
Nov 12
Top officer leaving
“(the “Company”) of his decision to resign as the Company’s Executive Vice President and Group President, Pharmaceuticals, effective as of December 1, 2025, to join a company in the healthcare industry.”
8-K on sec.gov
Oct 21
Top officer leaving
“(the “Company”) of her decision to resign as the Company’s Executive Vice President, Chief Operating Officer (“COO”) and interim group president of Medical Products and Therapies (“MPT”), effective as of October 29, 2025 (the “Transition Date”), to join a company in the healthcare industry.”
8-K on sec.gov

From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.

FDA, last 12 months

14 approvals or clearances and 39 recalls recorded by the FDA for this company and its listed subsidiaries.

Approvals and clearances

Recalls

From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.

Aug 170.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 units per case. Baxter Healthcare Corporation, Deerfield, IL, 60015, USA, Made i…Class I · Ongoing · Presence of particulate matter: Particulates identified as fiberglass

Aug 17Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL, 60016, Made in USA, NDC 00338-0719-06Class I · Ongoing · Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Aug 11Baxter Novum IQ Syringe Pump, Model Number 40800BAXUSClass II · Ongoing · A software issue that may occur during a Volume/Time (VOT) multi-syringe infusion when a syringe reaches empty and is replaced while a Volume To Be Infused (VTBI) remains.

Short sale volume: 48.2% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 60.3%. FINRA daily files, to Oct 5, 2026.

Fails to deliver: 43K shares (about $1.13M) were not delivered on time for settlement on Aug 24, 2026. SEC fails-to-deliver data.

Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.